Posted by Michael Wonder on 19 Mar 2024
Deverra Therapeutics granted FDA regenerative medicine advanced therapy and orphan drug designations for DVX101 (Dilanubicel) for the treatment of acute myeloid leukaemia
19 March 2024 - Deverra Therapeutics today announced that the US FDA granted regenerative medicine advanced therapy designation to its lead candidate (dilanubicel) for use in first-line treatment for acute myeloid leukaemia.
Dilanubicel was recently granted orphan drug designation for the treatment of acute myeloid leukaemia.
